Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study
- 18 September 2020
- journal article
- letter
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 61 (11), 2752-2755
- https://doi.org/10.1080/10428194.2020.1775217
Abstract
Several clinical studies have shown superiority of azacitidine compared to conventional care regimens in frail patients with MDS and AML [1–4]. However, clinical decision making with regards to dos...Funding Information
- Celgene Corporation
This publication has 9 references indexed in Scilit:
- RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysisLeukemia & Lymphoma, 2019
- The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study GroupHematological Oncology, 2018
- Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Blood Cancer Journal, 2018
- Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesBritish Journal of Haematology, 2016
- Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registryLeukemia, 2015
- Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA®registryLeukemia & Lymphoma, 2014
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002